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Abstract Endothelial dysfunction plays a major role in the
pathogenesis of atherosclerosis. Pro-inflammatory cytokines
such as interleukin-1L and tumour necrosis factor K activate
endothelial cells changing their resting phenotype to become pro-
adhesive, pro-thrombotic and pro-atherogenic. Phage display in
vivo biopanning has been used to identify peptide sequences that
home to diseased regions of the vessel wall in low density
lipoprotein receptor (LDLr) knockout mice. In LDLr knockout
mice, peptide sequence determinants exhibiting organ specificity
have been isolated. These sequences have applications for gene
delivery, drug delivery and for improving contrast agents for
vascular imaging. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Atherosclerosis is a focal disease of large- and medium-
sized arteries and results in the formation of discrete raised
lesions referred to as atherosclerotic plaques which occlude
the vessel lumen. When fully advanced, these plaques restrict
the £ow of blood through the vessel and this often results in
tissue ischaemia. Within the arterial wall, the intima is com-
posed mainly of a single endothelial cell monolayer. The en-
dothelium provides a sensory interface between the blood-
stream and the vessel wall and is often described as the
gatekeeper of vascular function [1]. Initiation of lesion forma-
tion is brought about as a result of various forms of insult to
the arterial endothelium which include pro-in£ammatory cy-
tokines and risk factors such as hypercholesterolaemia, smok-
ing, diabetes and hypertension [2]. This endothelial injury re-
sults in the endothelium developing a pro-adhesive, pro-
atherogenic, pro-thrombogenic phenotype which manifests it-
self as increased in£ammatory leukocyte adhesion, promotion
of smooth muscle cell migration and proliferation, modula-
tion of extracellular matrix composition, modulation of vas-
cular tone and susceptibility to thrombus formation [3]. Ani-
mal models of atherosclerosis include the apoE and low den-
sity lipoprotein receptor (LDLr) knockout mouse models
which, when maintained on a high fat ‘Western diet’, mimic
aspects of the human disease. Animals exhibit elevated levels
of circulating pro-in£ammatory cytokines, enhanced endothe-
lial expression of adhesion molecules at sites of lesion forma-
tion and display lesion formation [4^6].
The identi¢cation of targeting moieties that home speci¢-
cally to sites of atherosclerotic plaque development has nu-
merous potential therapeutic applications. These include tar-
geting gene, or small molecule, therapeutic agents for
modifying vessel wall pathology and as directed agents for
improving intravascular imaging [7]. Such targeting agents
may also identify novel disease-speci¢c ligands that may
lead to the identi¢cation of novel receptors and potential
new drug targets. In vivo biopanning was developed to iden-
tify peptide ligands, derived from phage display libraries, that
were capable of homing to speci¢c organs in a whole animal
[8]. This pioneering work was extended to identify a number
of tri-peptide motifs that homed to the vasculature of a range
of di¡erent organs such as the lung, spleen, skin and pancreas
[9]. Peptides capable of homing to angiogenic vessels of hu-
man breast carcinoma xenografts were later identi¢ed [10],
and one of the motifs isolated was the integrin binding
RGD motif. A further motif, the NGR sequence, was found
to be a cell adhesion molecule-speci¢c motif. These peptides
were conjugated to the cytotoxic cancer therapeutic agent
doxorubicin and when injected into mice bearing breast car-
cinomas, this agent resulted in inhibition of tumour growth
and metastasis and improved mouse survival for up to 6
months. This study was the ¢rst example where in vivo bio-
panning was used in a disease model of clinical relevance.
Further studies have identi¢ed peptides that mediate anti-tu-
mour activity. A peptide capable of inhibiting matrix metal-
loproteinase 9 activity by phage panning in vitro was identi-
¢ed with tumour growth and invasion being prevented when
the isolated peptide was injected into tumour bearing mice
[11]. Tumour homing peptides have also been successfully
used to direct pro-apoptotic peptides to angiogenic vessels
in mouse tumours [12].
We have used phage display in vivo biopanning to identify
peptide ligands that home speci¢cally to sites of diseased ves-
sel wall in the LDLr knockout mouse model of human athe-
rosclerosis. Further characterisation of one such peptide was
performed using an in situ binding protocol to frozen tissue
sections. Binding of this phage to diseased vessels was inhib-
ited by co-injection of phage with unconjugated peptide.
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2. Materials and methods
2.1. Phage display libraries
Libraries of random peptides expressed at the N-terminus of the fd
phage major coat protein pVIII, were created as described [13]. Each
library was constructed as a fusion between the wild type (wt) pVIII
major coat protein followed by a (Gly4Ser)3 spacer arm. Library
ON2604 of structure GGC(X)12C(G4S)3 was a constrained 12-mer
library (where X is any amino acid and (G4S)3 represents a glycine:
serine spacer arm) and was obtained as a gift from A¡ymax (Palo
Alto, CA, USA).
2.2. Determination of phage titre
Phage were titred in Escherichia coli strain AR1392 (A¡ymax, Palo
Alto, CA, USA) according to [14]. Dilutions of the phage to be titred
were prepared in PBS. Typically dilutions between 1032 and 1038
were prepared. 10 Wl of the diluted phage was added to 100 Wl of
growing cells and then incubated at 37‡C for 20 min without shaking.
The infected cells were then plated out on L-amp (100 Wg/ml) plates
and incubated overnight at 37‡C.
2.3. In vivo biopanning of phage display libraries in the LDLr knockout
mice
LDLr knockout mice were maintained for 24 weeks on a Western
diet to induce atherosclerotic lesions [6]. Mice were anaesthetised with
Avertin (0.017 ml/g). 1010 tu of the phage display library in a total
volume of 500 Wl DMEM (Sigma, Poole, Dorset, UK) was injected
into the mouse tail vein. 4 min after phage administration, the mouse
was perfused through the heart with 5^10 ml of DMEM. Regions of
vasculature that displayed lesions, namely the subclavian artery, the
carotid arteries and the aorta were dissected out, weighed and placed
in DMEM containing a cocktail of protease inhibitors (PI) used as
recommended by the manufacturers (Boehringer Mannheim). The ves-
sel segments were homogenised using a Dounce homogeniser and the
tissue homogenate was washed three times in ice-cold wash bu¡er
(DMEM-PI/1% BSA). 10 Wl of the homogenate was then titred in
triplicate, and the phage rescued from the tissue by E. coli infection
and phage ampli¢cation. A total of 250 individual colonies were se-
lected from round 1 of the biopanning procedure and ampli¢ed in E.
coli. For the second round of biopanning, 109 tu of puri¢ed phage was
then re-injected into a second LDLr knock-out mouse. The whole
panning and ampli¢cation process was repeated twice more. 100
clones from rounds 2 and 3 were then selected for sequencing. Pep-
tides or peptide motifs that appeared consistently in rounds 2 and 3 of
the panning process were retained for DNA sequencing and bioinfor-
matics analysis.
2.4. DNA sequencing and bioinformatics
Samples were sequenced using the automated ABI sequencing fa-
cilities at GlaxoWellcome using primers to the p8V5 phagemid, se-
quence, 5P-TGAGGCTTGCAGGGAGTC-3P. Peptide sequences were
aligned using the GCG (Wisconsin) software package. Peptide identi-
ties were compared using an analysis script (A. Lewis, unpublished).
2.5. Organ-speci¢c homing of individual clones
Speci¢city of phage homing to key organs in vivo was determined
by individual phage recoveries from tissue homogenates and by testing
for selective inhibition of homing by the unconjugated peptide. Pep-
tides were synthesised with an N-terminal acetylation and were HPLC
puri¢ed (Sigma Genosys) and reconstituted in sterile distilled water.
Free peptide (1 mg) was co-injected with 1010 tu of the speci¢c phage
clone. Test organs and regions of diseased vasculature were isolated,
homogenised and the number of phage recovered per gram of tissue
determined by ampli¢cation in E. coli as described above. All phage
titering experiments were carried out in triplicate. A control, insertless
phage clone was injected into mice in order to determine background
levels of phage binding.
2.6. In vitro binding of homogeneous phage clones to frozen tissue
sections
Frozen tissue sections of diseased mouse vasculature were cut at
7 Wm and ¢xed in ice-cold acetone. After rehydration in PBS, the
sections were incubated in PBS/0.03% H2O2 for 20 min at room
temperature (RT), followed by a 1 h block in PBS/2% BSA. Homo-
geneous phage preparations at concentrations of 109, 108 and 107 tu
per section were applied for 2 h at RT. Following three washes with
PBS/0.1% Triton X-100 and PBS, rabbit anti-fd phage antibody (Sig-
ma) was applied to the sections for 1 h at RT at 1:1000 dilution. After
a further three washes with PBS/0.1% Triton X-100 and PBS, bio-
tinylated anti-rabbit IgG antibody was applied to the sections at
1:200 dilution. PECAM-1 staining, to show endothelial cell integrity,
was performed using an antibody directed against PECAM-1 (RpD
systems) at 1:100 dilution. Antibody detection was then carried out
using the Vectastain Elite kit (Vector Laboratories). In all experi-
ments, a minus-phage and a minus-anti-fd antibody control section
was incorporated.
3. Results
3.1. Sequential enrichment of phage homing to atherosclerotic
vasculature in the LDLr knockout mouse
To demonstrate that we could enrich for a heterogeneous
population of phage capable of homing to diseased vessel
wall, sequential rounds of biopanning were performed in the
LDLr knockout mouse (Fig. 1). 1010 of the constrained li-
brary phage ON2604, were injected into the tail vein of an
LDLr knockout mouse previously maintained on a Western
diet. Following circulation of the phage, vascular perfusion
with DMEM and animal sacri¢ce, diseased areas of vascula-
ture were removed. The number of phages recovered per gram
of tissue was determined. The phage eluates were ampli¢ed
and the biopanning process was repeated a further two times
yielding an increase in phage recovery from diseased vas-
culature of approximately 1000 times (Fig. 1). 100 clones
were selected for sequence analysis. Ten clones, sequences of
which are shown in Table 1, were isolated repeatedly in
rounds 2 and 3 of panning. One clone (2.6) of sequence
CLVEAYPGL*VRSC (where * denotes a stop codon) was
picked for further characterisation.
3.2. Binding speci¢city of phage clone 2.6 to atherosclerotic
tissue
Phage clone 2.6 was tested for binding speci¢city to dis-
eased vasculature from the LDLr knockout mouse (Fig. 2).
Regions of vasculature displaying advanced atherosclerotic
lesions such as the aorta were isolated from an LDLr knock-
Fig. 1. Sequential enrichment of phage homing to atherosclerotic
vasculature in the LDLr knockout mouse. 1010 tu of constrained
12-mer phage library ON2064 was sequentially panned for three
rounds. Phage recovery was determined as tu phage per gram of tis-
sue.
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out mouse. Frozen sections of tissue (7 Wm) were incubated
with 108 tu of undiluted phage clone 2.6 to allow binding. In
addition, phage binding was performed at a range of concen-
trations using serial dilutions of phage at 1010, 109, 108 and
107 tu per section. Results are presented for tissue sections
incubated with 108 tu phage per section. Phage binding was
determined immunohistochemically. Phage binding was local-
ised predominantly within the plaque and on the endothelium,
with lesser binding detectable in the media and the adventitia
(Fig. 2A). Intense endothelial cell staining was detected in a
diseased section of aorta in the absence of a neointimal lesion
(Fig. 2B). Sections of diseased vessel probed with a homoge-
neous phage preparation lacking a peptide insert, or clone 2.6
without secondary antibody functioned as negative controls
Fig. 2. Selective binding of phage clone 2.6 to regions of atherosclerotic plaque development. 108 tu of clone 2.6 or a control insertless phage
was added to frozen tissue sections of vasculature from an LDLr knockout mouse and binding detected immunohistochemically using antibod-
ies to the phage coat protein. Scale bar represents 10 Wm. A: Binding is within the plaque (P) and on the endothelium (green arrow). L = lu-
men. B: Endothelial staining in a region of vessel adjacent to plaque development (green arrow). L = lumen. C: Insertless phage binding to
atherosclerotic vessel. P = plaque, L = lumen. D: Staining in atherosclerotic vessel in the absence of secondary biotinylated anti-rabbit IgG anti-
body. L = lumen.
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(Fig. 2C,D). There was no detectable binding of phage clone
2.6 to the vasculature of a non-diseased mouse of the same
C57 black parental strain. The presence of an intact endothe-
lial cell layer in both the diseased and control tissue sections
was determined to be positive by immunohistochemistry using
PECAM-1 antibody (data not shown).
3.3. Di¡erential binding of phage clone 2.6 to artery and kidney
from LDLr knockout mouse
Injection of 1010 tu of phage clone 2.6 into the LDLr
knockout mouse resulted in signi¢cant phage recovery from
both isolated diseased vasculature and the kidney when com-
pared to the recovery of a control non-speci¢c insertless phage
clone (Fig. 3). A high level of non-speci¢c phage binding to
other organs isolated in this study, such as liver, spleen and
lung was observed (data not shown, [9]).
3.4. Competition for phage homing in vivo by unconjugated
peptides
In order to determine whether there was in vivo speci¢city
for this phage to areas of diseased vasculature, a selection
and competition biopanning experiment was performed.
Two peptide preparations were used, a linear 9-mer peptide
(CLVEAYPGL) designated peptide 1 and a constrained 14-
mer peptide, where a serine residue had been inserted into the
site of the stop codon (CLVEAYPGLSVRSC) and was des-
ignated peptide 2. Co-injection of 1010 tu of the phage clone
2.6 with each of the free peptides resulted in a 26% binding
inhibition of phage to the vasculature by peptide 2. No sig-
ni¢cant inhibition of binding was demonstrated by the linear
9-mer peptide (Fig. 4).
4. Discussion
In this paper we demonstrate the application of in vivo
biopanning to a murine model of disease, the LDLr knockout
mouse model of atherosclerosis. The expression of endothelial
markers ICAM-1, VCAM-1, E-selectin and PECAM-1 has
been extensively studied in both the LDLr and the apoE
knockout mouse models and shown to be upregulated at sites
of lesion development [5,15]. These observations, taken to-
gether with previous studies [9] suggest that the vascular en-
dothelium displays a heterogeneous range of markers that
may function as molecular addresses. By sequential panning
of a constrained, cyclic 12-mer phage library, a phage popu-
lation enriched 1000 fold was obtained after three rounds of
biopanning. A previous study reported an enrichment ratio of
100 over three rounds of biopanning for phage that homed to
lung, kidney and brain [9]. Our data suggests that a highly
signi¢cant enrichment of phage speci¢c to the diseased vascu-
lature was evident between each round of panning in the
LDLr knockout mouse.
Sequence analysis of 100 clones picked from rounds 2 and 3
of panning revealed 10 peptide motifs that appeared repeat-
edly in each round, of which one motif, LVEA was the most
common. The full 12 amino acid sequence incorporated a stop
codon at position 9, suggesting that a truncated fusion prod-
uct may have been created. A stop codon does not necessarily
mean that a truncated product has been created since there
are examples where translational readthrough may occur from
ORF within phage display libraries. This was demonstrated
Table 1
Peptide sequences identi¢ed following in vivo panning in the LDLr
knockout mouse
Clone Sequence
2.6 CLVEAYPGL*VRSC
2.20 CRM*KARRTVPNSC
3.5 CVR*SETCERYKTC
3.8 CRERVSPLKSM*WC
3.18 CRSRRV*SWVHSLC
3.44 C*LRCRMTMPVRRC
3.46 CL*RFCRVRGTFTC
3.70 CMGYGW*PPVRDGC
3.79 CHANPE*RCMTAWC
3.97 CLASALWNYES*AC
*Denotes a stop codon within the peptide sequence.
Fig. 3. Di¡erential binding of phage clone 2.6 to artery and kidney
from LDLr knockout mouse. 1010 tu of phage were injected into a
mouse and phage recovered from kidney and arteries. Recovery is
expressed as tu phage per gram tissue.
Fig. 4. Competition for phage homing in vivo by unconjugated pep-
tides. 1010 tu of phage clone 2.6 was injected into an LDLr knock-
out mouse with a 9-mer (peptide 1) or 12-mer peptide (peptide 2).
An insertless phage preparation at 1010 tu per animal was used to
determine background binding.
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by a translational recording mechanism whereby ribosomes
switched reading frames or read past stop codons when en-
countering a signal in the nucleotide sequence of the mRNA
[16]. Isolation of peptide sequences which include stop codons
is a common occurrence when using this technique since they
often represent faster growing phage clones. Nevertheless,
such truncated displayed sequences have shown potential in
homing experiments targeted at speci¢c tissues (R. Pasqualini,
personal communication). Clone 2.6 showed speci¢c homing
to regions of the vascular endothelium of diseased vessels and
within the atherosclerotic plaque. This is the ¢rst time that
this has been achieved in vivo. Biopanning with clone 2.6
resulted in signi¢cant phage recovery from both isolated dis-
eased vasculature and the kidney, when compared to the re-
covery of a control non-speci¢c insertless phage clone. A high
level of non-speci¢c phage binding to other organs isolated in
this study, such as liver, spleen and lung was observed (data
not shown). Non-speci¢c phage homing to liver, spleen and
lung tissue has previously been observed [8]. This would be
expected in tissues such as the liver and spleen since these
organs form part of the reticulo-endothelial system and rep-
resent ‘sinks’ for non-speci¢c phage binding.
The enhanced recovery of clone 2.6 from the kidney may be
due to the observation that atherosclerosis in the renal arteries
is very common in man [17] and has also been demonstrated
in murine models of atherosclerosis [4]. However it may well
be possible that some non-speci¢c phage accumulation may
have occurred due to renal mesangial cell phagocytosis.
Competition for phage binding, as determined by phage
recovery was greater with the 12-mer as opposed to the 9-
mer unconjugated peptide which may suggest the phage par-
ticle was more likely to have produced a fully constrained 12-
mer fusion product whereby readthrough of the stop codon
had occurred.
The LVEA motif displayed sequence homology to VCAM-
1, ecNOS, TNF-K receptor and VEGF receptor. The role of
each of these molecules in the pathogenesis of atherosclerosis
is well documented [2]. Whilst it is recognised that clone 2.6
could be represented in these proteins, one cannot formally
rule out the possibility that this motif may well form part of a
novel cell surface receptor.
Further studies in our laboratory will be aimed at address-
ing the exploitation of this peptide as an agent for targeting
both drug and gene delivery to sites of atherosclerosis. Con-
jugation of targeting peptide moieties to adenoviral, retroviral
and liposome vectors presents enormous potential for improv-
ing future gene therapy technology [18,19]. It may also be
feasible to the couple peptide targeting together with a tran-
scriptional targeting strategy such as promoters that respond
to laminar shear stress [20]. In this manner distinct foci of
wounded endothelium may be targeted for gene therapy. Fi-
nally, an interesting extension of the application of targeted
liposomes may be provided by their utility in improving imag-
ing agents for atherosclerosis [21].
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